FierceBiotech
Charles River Laboratories is expanding its services into the early discovery setting, offering high-speed pharmacokinetics screening of compounds’ underlying biology to help companies identify small-molecule candidates.
The contract research organization has also built out its PK capabilities near pharmaceutical and biotechnology hubs in San Francisco and The Netherlands, the company said. This includes capacity for PK screening regardless of therapeutic area, to support drug discovery from initial testing of potential compounds to late-stage candidate selection and preclinical studies.